General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Bausch Health, Canada Inc.
Indication:
Active mild to moderate distal ulcerative colitis
Last updated February 2, 2024
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Multiple Indications
Last updated January 25, 2024
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Moderately to severely active Crohn's disease in adults
Last updated January 24, 2024
Status:
Concluded with an LOI
Manufacturer:
Paladin Labs Inc.
Indication:
Acute bacterial skin and skin structure infections
Last updated January 23, 2024
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Active lupus nephritis
Last updated January 18, 2024
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Systemic lupus erythematosus
Last updated January 18, 2024
Status:
Concluded with an LOI
Manufacturer:
Sobi Canada Inc.
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH) in adult patients who have an inadequate response to, or are intolerant of, a C5 inhibitor
Last updated January 17, 2024
Status:
Concluded without agreement
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Breast cancer, Locally advanced, inflammatory, or early stage HER2-positive (either 2 cm in diameter or node positive), for neoadjuvant treatment of patients (in combination with trastuzumab and chemotherapy)
Last updated December 21, 2023
Status:
Concluded with an LOI
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated December 17, 2023
Status:
Concluded with an LOI
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated December 17, 2023